Join us on Wednesday, April 30^th for this CME/MOC-accredited webinar
5:00 PM – 6:00 PM ET

Wednesday​, April 30, 2025
5:00 PM – 6:00 PM ET
Live CME/MOC-accredited webinar

Topics to Be Discussed

• Current Management of Myelofibrosis
• Novel Investigational Strategies

Target Audience
This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of myelofibrosis.

Learning Objectives
Upon completion of this activity, participants should be able to

• Use an understanding of disease biology and natural history to effectively counsel patients diagnosed with myelofibrosis (MF) regarding their long-term prognosis.
• Analyze how age, performance status, prior therapeutic exposure and other biological and disease-related factors affect the selection and sequencing of therapy for patients with primary and secondary MF.
• Appraise available research findings informing the safety and efficacy of approved JAK inhibitors for patients with MF, including those with thrombocytopenia, anemia or compromised renal function.
• Review available research data with and the current clinical role of novel JAK inhibitors in treatment for patients with MF and severe thrombocytopenia.
• Evaluate published research findings with JAK inhibitors for patients with MF and anemia to optimize decision-making for this population.
• Assess available research findings with combination regimens incorporating JAK inhibitors and other novel therapies, and consider the potential clinical application of these approaches.
• Increase participation in active research protocols by counseling appropriately selected patients regarding the biological rationale for and available efficacy and safety data with novel investigational agents and strategies for MF.

CE Credit
CME and ABIM MOC credit links will be emailed to each participant within 3 business days of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for this activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. 

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology. 

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Prof Harrison — Advisory Committees: Galecto Inc, Geron Corporation, GSK, Incyte Corporation, Karyopharm Therapeutics, Keros Therapeutics, Novartis, Silence Therapeutics, Sobi; Consulting Agreements: Galecto Inc, Geron Corporation, GSK, Incyte Corporation, Karyopharm Therapeutics, Keros Therapeutics, Novartis, Silence Therapeutics, Sobi, Takeda Pharmaceutical Company Limited; Contracted Research: Galecto Inc, Geron Corporation, GSK, Incyte Corporation, Karyopharm Therapeutics, Novartis, Silence Therapeutics, Sobi; Data and Safety Monitoring Boards/Committees: Galecto Inc, Incyte Corporation, Novartis, Silence Therapeutics; Speakers Bureaus: AOP Health, GSK, Incyte Corporation, Novartis. Dr Mascarenhas — Consulting Agreements: Bristol Myers Squibb, Disc Medicine, Geron Corporation, GSK, Incyte Corporation, Italfarmaco SpA, Kartos Therapeutics, Karyopharm Therapeutics, Keros Therapeutics, Merck, MorphoSys, Novartis, PharmaEssentia, Roche Laboratories Inc, Sobi, Sumitomo Dainippon Pharma Oncology Inc; Contracted Research: AbbVie Inc, Bristol Myers Squibb, Disc Medicine, Incyte Corporation, Italfarmaco SpA, Kartos Therapeutics, Karyopharm Therapeutics, Novartis, PharmaEssentia, Sobi; Data and Safety Monitoring Boards/Committees: Incyte Corporation.

MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, ADC Therapeutics, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Clovis Oncology, Coherus BioSciences, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Hologic Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, and Tesaro, A GSK Company.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from Geron Corporation and Incyte Corporation.